A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM AND AVIBACTAM ± METRONIDAZOLE IN NEONATES AND INFANTS FROM BIRTH TO LESS THAN 9 MONTHS OF AGE WITH SUSPECTED OR CONFIRMED INFECTIONS DUE TO GRAM-NEGATIVE PATHOGENS REQUIRING INTRAVENOUS ANTIBIOTIC TREATMENT

The purpose of this study is to learn about the safety and effects of ATM-AVI for the possible treatment of infections caused by a type of bacteria called gram-negative bacteria.
The study medicine is a combination of an antibiotic, aztreonam (ATM), and another medicine, avibactam (AVI), which is used to help stop bacteria from being resistant to antibiotics. Antibiotics are medicines that fights bacteria and infections.
The study will include newborns and infants up to 9 months of age who are admitted in the hospital.
The study is conducted in 2 parts: Part A and Part B.
In Part A, all participants will receive a single intravenous (injected directly into a vein) infusion of ATM-AVI. This is to study the safety and effects of a single amount.
In Part B, all participants will receive multiple intravenous infusions of ATM-AVI as treatment for a possible or confirmed infection with gram-negative bacteria.

开始日期2024-09-25

申办/合作机构

Pfizer Inc.

[+1]

CTR20233317

/ Recruiting临床2期

一项在患有严重革兰阴性菌感染（包括复杂性腹腔内感染）的9 月龄至18 岁以下儿童受试者中研究氨曲南-阿维巴坦静脉给药联用或不联用甲硝唑与最佳可用治疗（BAT）相比的药代动力学、安全性、耐受性和有效性的IIa 期、多中心、观察者设盲、随机双臂研究

该研究拟使用的生物样本来自于确诊为严重革兰阴性菌感染的受试者。本研究的研究目的为在 9 月龄至<18 岁受试者中评估 ATM－AVI用于治疗严重革兰阴性菌感染的 PK 和在 9 月至<18岁受试者中评估 ATM－AVI 和BAT用于治疗严重革兰阴性菌感染的安全性和耐受性及疗效，拟使用全血、血清等人类遗传资源进行分析和检测。

开始日期2024-07-24

申办/合作机构

Pfizer Inc.

[+2]

NCT05639647

/ Recruiting临床2期

A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTION

The purpose of this study is to evaluate how Aztreonam (ATM) and Avibactam (AVI) are processed in pediatric participants. This study also aims to understand participant safety and effects in pediatric participants.
The study is seeking participants who are:
* 9 months to less than 18 years of age
* Hospitalized
* Suspected/known to have a gram-negative infection
* Receiving intravenous (iv, given directly into a vein) antibiotics
* Being treated for complicated infections of various body parts that includes the abdomen, urinary tract, blood stream, and lungs.
* Participants will receive either ATM-AVI or best available therapy (BAT).
* Both therapies will be given through a vein.
* Participants with complicated abdominal infections will also receive iv Metronidazole (MTZ). Patients with cIAI and Cockayne Syndrome are excluded due to a risk of severe hepatotoxicity with the use of MTZ. - Participants on ATM-AVI treatment who have anaerobic infections will also receive iv MTZ at the study doctor's discretion.
* The iv dose of ATM-AVI will be based on the participant's weight and kidney function.
* The study doctor will determine the iv dose of BAT.
* During the first 2 study days, participants on ATM-AVI therapy will have 5 blood draws in small quantities.
* Starting on day 4, the study doctor will decide if participants may be switched to oral therapy.
* Participants will receive a maximum of 14 days of ATM-AVI treatment.
* After discharge from the hospital, 1 study visit may be required.
* Depending on the participant's response, the study duration will be from 33 to 50 days.
* The investigator will contact participants by phone 28 to 35 days after the last study treatment to check participants health status.

开始日期2023-04-18

申办/合作机构

Pfizer Inc.

100 项与阿维巴坦钠/氨曲南相关的临床结果

登录后查看更多信息

100 项与阿维巴坦钠/氨曲南相关的转化医学

登录后查看更多信息

100 项与阿维巴坦钠/氨曲南相关的专利（医药）

登录后查看更多信息

项与阿维巴坦钠/氨曲南相关的文献（医药）

2025-02-01·INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Multiple mechanisms mediate aztreonam-avibactam resistance in Klebsiella pneumoniae: Driven by KPC-2 and OmpK36 mutations

Article

作者: Xiang, Xinli ; Zhou, Tieli ; Kong, Jingchun ; Zhang, Jia ; Sun, Yao ; Qian, Changrui ; Zhang, Xiaotuan

Aztreonam-avibactam (ATM-AVI) is a promising β-lactam/β-lactamase inhibitor combination with an antimicrobial spectrum covering serine carbapenemase- or metallo-β-lactamase-producing Enterobacterales. Although ATM-AVI has not been widely used in clinical practice, resistance to it in Escherichia coli has been widely reported. In this study, we investigated an ATM-AVI-resistant Klebsiella pneumoniae strain, designated as 1705R, derived from K. pneumoniae ATCC BAA-1705 by induction, with a minimal inhibitory concentration of 128 µg/mL. The 1705R strain contained two copies of the bla_KPC-2 variant, which encodes for a K. pneumoniae carbapenemase (KPC) variant with a Ser109Pro substitution, as well as a premature termination in OmpK36 and OmpK35 porins. This KPC variant decreased susceptibility to ATM-AVI by four-fold and demonstrated a reduced affinity for ATM and AVI in molecular docking analysis. In porin-deficient strains harbouring this KPC variant, ATM-AVI susceptibility was further diminished, exhibiting a 32-fold reduction. Whole-genome sequencing revealed that the transposition of Tn4401 carrying bla_KPC from the IncFIB/FIIK plasmid into the ColRNAI plasmid produced a second copy of bla_KPC. Quantitative polymerase chain reaction revealed that the copy number of bla_KPC and its carrier plasmid increased, which significantly up-regulated their mRNA expression. Overexpression of the AcrAB-TolC efflux pump may also be associated with high levels of ATM-AVI resistance. Furthermore, collateral susceptibility and costs of growth and biofilm formation developed after the acquisition of ATM-AVI resistance. This study demonstrates that multiple molecular mechanisms collectively contribute to ATM-AVI resistance in K. pneumoniae 1705R strain, which may represent a mode of resistance to ATM-AVI.

2024-12-01·Microbial Drug Resistance

A Selective Culture Medium for Screening Aztreonam-Avibactam Resistance in Enterobacterales and Pseudomonas aeruginosa

Article

作者: Nordmann, Patrice ; Poirel, Laurent ; Herrera-Espejo, Soraya ; Cordero, Elisa ; Pachón-Ibáñez, María Eugenia ; Bouvier, Maxime

Aztreonam/avibactam (ATM/AVI) has been recently approved drug for clinical use in the European Union. The aim of this study was to develop and evaluate a novel selective medium for the isolation of ATM/AVI-resistant strains (Super ATM/AVI selective medium) to help to control their spread. Minimum inhibitory concentrations of ATM/AVI were determined using the broth microdilution method for 77 Gram-negative isolates, including 62 Enterobacterales and 15 Pseudomonas aeruginosa. The Super ATM/AVI selective medium was elaborated using optimal final concentrations of ATM at 5 mg/L and AVI at 4 mg/L, being supplemented with amphotericin B and vancomycin to prevent growth of yeasts and Gram-positive bacteria and with ZnSO₄ to optimize the expression of metallo-β-lactamase producers. Super ATM/AVI showed high sensitivity (94.6%) and specificity (100%) at a detection limit of 10³ CFU/mL.

2024-12-01·PHARMACOTHERAPY

Aztreonam–avibactam: The dynamic duo against multidrug‐resistant gram‐negative pathogens

Review

作者: Al Musawa, Mohammed ; Herbin, Shelbye R. ; Caniff, Kaylee E. ; Van Helden, Sean R. ; Bleick, Callan R. ; Rybak, Michael J.

Abstract:

Antimicrobial resistance poses a significant public health challenge, particularly with the rise of gram‐negative hospital‐acquired infections resistant to carbapenems. Aztreonam–avibactam (ATM–AVI) is a promising new combination therapy designed to combat multidrug‐resistant (MDR) gram‐negative bacteria, including those producing metallo‐β‐lactamases (MBLs). Aztreonam, a monobactam antibiotic, is resistant to hydrolysis by MBLs but can be degraded by other β‐lactamases. Avibactam, a novel non‐β‐lactam β‐lactamase inhibitor, effectively neutralizes extended‐spectrum β‐lactamases (ESBLs) and AmpC β‐lactamases, restoring aztreonam's efficacy against resistant pathogens. This review covers the chemistry, mechanisms of action, spectrum of activity, pharmacokinetics, pharmacodynamics, and clinical efficacy of ATM–AVI. ATM–AVI combination has shown efficacy against a wide range of resistant Enterobacterales and other gram‐negative bacteria in both in vitro and clinical studies. Pharmacokinetic and pharmacodynamic analyses demonstrate that ATM–AVI maintains effective drug concentrations in the body, with dose adjustments recommended for patients with renal impairment. Clinical trials, including the REVISIT and ASSEMBLE studies, have demonstrated the safety and efficacy of ATM–AVI in treating complicated intra‐abdominal infections (cIAI), urinary tract infections (UTIs), and hospital‐acquired pneumonia (HAP) caused by MDR gram‐negative pathogens. The European Medicines Agency (EMA) has approved ATM–AVI for these indications, and further research is ongoing to optimize dosing regimens and expand its clinical use. This combination represents a critical advancement in the fight against antimicrobial resistance, offering a new therapeutic option for treating severe infections caused by MDR gram‐negative, including MBL‐producing, bacteria.

项与阿维巴坦钠/氨曲南相关的新闻（医药）

2025-01-17

·Pharmaceutical Technology

FDA beats EMA to most approved new drugs in 2024

The FDA approved five fewer novel medicines than in 2023 while the EMA improved its tally by seven. Image credit: Shutterstock / Tamakhin Mykhailo. The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in 2024. On 15 January, the two agencies released respective lists of medicines approved last year. The FDA approved 50 novel drugs that contained an active ingredient not previously approved by the agency, whilst the EMA authorised 46 new medicines. Whilst racking up 50 novel drug approvals, the FDA approved fewer than it did in 2023, when there were 55 greenlit to market . Conversely, the EMA’s 2024 figure of 46 was a step up from the 39 new active substance drugs approved in 2023. The highest proportion of new drugs approved by the EMA came in haematology/haemostaseology indications, with ten of the 12 approved medicines in this area containing a new active ingredient. Overall, however, oncology had the highest number of new drugs, matching trends seen in previous years. The FDA meanwhile highlighted the importance of rare diseases, reporting that over half its novel approvals came in orphan diseases that affect fewer than 200,000 people in the US. The FDA added that 68% of its novel drugs were approved in the US before any other country. Mirrored approvals Both the FDA and EMA approved Pfizer’s Hympavzi (marstacimab-hncq) for the treatment of adults and adolescents with severe haemophilia A or B without inhibitors. Hympavzi’s entry to market marked a significant advancement in treatment options available for patients with the rare disease, becoming the first approved anti-tissue factor pathway inhibitor. In the hepatological space, both the FDA and EMA have approved Ipsen’s Iqirvo (elafibranor) and Gilead’s Livdelzi (seladelpar), the latter being marketed at Seladelpar Gilead in Europe. The drugs were approved for the treatment of primary biliary cholangitis, a chronic disease that can eventually lead to liver failure. The agencies were also aligned on ARS Pharmaceuticals adrenaline-based nasal spray for anaphylaxis treatment. Marketed as neffy in the US and Eurneffy in Europe, the drug became the first needle-free adrenaline option for emergency treatment of allergic reactions. Its entry to market, despite a hiccup in 2023 when the FDA declined to approve it, is seen as a more convenient alternative to EpiPen. Neuro differences Perhaps the most significant contrasts came in neurological indications. First came the approval of the new Alzheimer’s treatment Kisunla (donanemab) by the FDA in July 2024. The drug, which is still being reviewed by the EMA, provides direct competition to Eisai and Biogen’s Leqembi (lecanemab), which the EMA approved in late 2024, more than a year later than the FDA. Both treatments are monoclonal antibodies that target beta plaques in the brain, though Kisunla is infused every four weeks rather than Leqembi’s two. In September 2024, the FDA approved the first new schizophrenia drug in more than 30 years, courtesy of Bristol Myers Squibb’s (BMS) Cobenfy (xanomeline and trospium chloride). The approval validated the company’s $14bn acquisition deal for Karuna Therapeutics in which it gained rights to the candidate. BMS has not yet submitted Cobenfy to the EMA for marketing authorisation, though there are plans to run a UK trial in Oxford in 2025. Cobenfy is forecast to reach blockbuster status by 2028, as per GlobalData’s Pharma Intelligence Center. GlobalData is the parent company of Pharmaceutical Technology . Medications that received EMA approval but not FDA approval last year include Egetis Therapeutics’ Emcitate (tiratricol) and Pfizer’s Emblaveo (aztreonam-avibactam). Emcitate is the first treatment approved for peripheral thyrotoxicosis in patients with the ultra-rare chronic disease Allan-Herndon-Dudley syndrome while Emblaveo is indicated for certain types of infections by aerobic Gram-negative bacteria resistant to antibiotics.

上市批准并购

2024-11-04

·E药经理人

倒计时1天！辉瑞、罗氏、强生、诺和诺德、碧迪进博“晒肌肉”，谁家“尖货”最多？

Show time！第七届中国国际进口博览会(第七届进博会)开幕在即，又到了在华跨国药企集体“秀肌肉”的重要时刻。今年不同在于，创新含量分外高，多款“全球首个”“全球唯一”“中国首个”前沿新兴技术、创新药及诊疗方案将登场“首秀”。医疗器械及医药保健展区将集聚全球十大医疗器械企业、超十家世界500强制药企业，超400项代表性新产品、新技术、新服务斌彩纷呈。 E药经理人在持续关注进博会的第7年，明显感知到，当新兴技术疗法的迭代速度成为行业最大的变量，当成熟产品价格面对被“钳制”的命运，大型跨国药企洞悉唯有加速将资源转舵至聚焦前沿创新，才能适应行业变局。同时，当前中国市场蕴含了持续增长且巨大的潜力，MNC近两年在不断升级中国市场战略，加速融入中国创新生态，在利好政策推动下加速创新产品落地，升级中国研发中心地位，探索在中国不分治疗领域进行全球同步早期研究路径。同时，快速以更优化的组织架构与策略，深耕中国市场。这一次，几乎每家MNC都拿出了自家最前沿、最具竞争力、最具爆点的创新“家底”。从“展品”到“商品”，再到重大投资及落地，进博会的“溢出效应”，也愈发坚定了药企们长期深耕中国市场的信心。一起看看此次进博会，都有哪些燃点？哪家企业的家底最雄厚？（按企业首字母排序）安进本次安进将带来6款创新产品，其中包括骨健康领域中国首个获批用于骨质疏松症治疗的抗RANKL单抗药物普罗力（地舒单抗注射液60mg），以及和优时比公司共同研发的用于抗骨质疏松新药罗莫佐单抗（Evenity）。自2012年进入中国市场以来，安进聚焦四个治疗领域，即心血管疾病、骨健康、炎症及肿瘤，持续引入创新产品。与此同时，安进积极携手各方倡导采用“预测与预防”这一模式来投资建设有韧性的医疗系统，应对包括骨质疏松在内的慢性疾病，从多方面入手，改进疾病防控，稳定医疗成本，助力健康老龄化和健康中国2030。拜耳拜耳将集中亮相更多医疗健康和农业科技领域的创新产品及前沿技术服务。处方药领域，全方位展示心血管、肿瘤及女性健康等领域的创新产品及适应症。今年进博会将见证可申达（非奈利酮）取得心衰治疗领域临床研究新突破、拜阿司匹灵以全新大包装和环保材料焕新上市。用于眼科治疗的Eylea 8mg在欧盟获批后也将首展进博会，该展品已获CDE受理用于治疗新生血管性（湿性）年龄相关性黄斑变性（nAMD）的上市申请。此外，在肿瘤治疗领域发布最新试验结果的诺倍戈 ARANOTE、获FDA突破性疗法认定和CDE突破性治疗品种认定的肺癌新型靶向治疗药物BAY 2927088都将在进博会现场展示讲解。勃林格殷格翰勃林格殷格翰始终视中国为重点市场与创新高地。站在第七届进博会新起点，勃林格殷格翰将持续践行“在中国，为全球”的长期承诺。未来五年，公司将持续加大在华研发投入。其中，人用药品业务预计到2030年将收获25项注册审批成果。动物保健业务未来五年预计将有超过10种新产品、新适应症获批上市，覆盖经济动物和伴侣动物的关键物种。勃林格殷格翰大中华区总裁兼CEO高皓廷（Mohammed Tawil）表示：“进博会是推动中国市场全球开放共享的绝佳平台。连续六年打卡进博会彰显了勃林格殷格翰对中国市场的不变初心，也印证了我们扎实推动在华加速创新的坚定信心。” 复星医药 2024年，创立30周年的复星医药连续第7年参展进博会。作为全球领先的医疗创新整合者，复星医药借助进博会的国际性开放平台，将多个“中国首款”、“全球首个”的领先技术与创新产品落地中国，推进创新产品的本土化。今年，复星医药将在7.1馆医疗器械及医药保健区（展位号：7.1B3-02）继续携手全球合作伙伴带来多款创新药及医疗器械产品，覆盖实体瘤、血液瘤、免疫炎症等核心治疗领域，以及神经系统疾病创新诊疗解决方案。亮相的核心产品包括，已在中国获批的Ion支气管导航操作控制系统及达芬奇手术机器人、中国首款获批的CAR-T细胞治疗产品奕凯达、全球首款新型无液氦128通道脑磁图系统以及全球最尖端的无创经颅治疗科技产品之一“磁波刀”等。辉瑞本届进博会，辉瑞将以“辉瑞卅五中国情超越昨天向未来”为主题，带来24款全球领先的创新产品及解决方案，其中4款为首发首秀，包括全球首个针对金属β-内酰胺酶（MBLs）的β-内酰胺类/β-内酰胺酶抑制剂组合思福诺（注射用氨曲南阿维巴坦钠）、前列腺癌领域的新型双重机制PARP抑制剂甲苯磺酸他拉唑帕利胶囊、具有独特作用机制的血友病疗法马塔西单抗以及靶向B细胞成熟抗原和CD3的双特异性抗体埃纳妥单抗等。除了创新实力的展现，今年进博会期间，辉瑞中国2030战略也将重磅发布，彰显未来持续深耕中国的承诺。罗氏今年是罗氏制药在华成立三十周年。作为医疗器械及医药保健展区面积最大的展商之一，罗氏以“华彩三十，聚氏未来”为主题、七赴进博会之约，于1000平方米的进博展台上全面展示超过30款已上市和即将在华上市的全产品矩阵及创新解决方案，重磅推出3款即将在华获批的全球创新产品——中国首个且唯一PI3Kα抑制剂伊那利塞（Inavolisib）、首个在全球上市的用于B细胞淋巴瘤治疗的CD20/CD3双特异性抗体创新药Lunsumio（Mosunetuzumab）、全球首个也是唯一一个同时获批用于治疗复发型多发性硬化和原发进展型多发性硬化的药物Ocrevus（Ocrelizumab，奥瑞利珠单抗）。罗氏在华未来管线也首次亮相进博舞台，重点展示慢阻肺领域、全球首创的全人源化抗ST2单克隆抗体Astegolimab。此外，罗氏还带来了多个“进博宝宝”和明星产品，比如抗流感创新药速福达（玛巴洛沙韦）、全球首个作用于复发难治淋巴瘤的靶向CD20/CD3的双特异性抗体创新药高罗华（格菲妥单抗）等。美纳里尼美纳里尼是意大利最大的医药公司，深耕中国医药市场十余年，始终坚持以“健康，是我们对生命的承诺”为使命，积极拓展与国内外优秀的行业伙伴的合作。今年是美纳里尼首次亮相进博会，将于11月8日向公众展示美纳里尼男性健康、皮肤医美、抗过敏、消化、内分泌、疼痛管理等多元领域优质原研进口产品。同时，通过与上药康德乐的合作新篇章，美纳里尼将进一步赋能原研药品的引进和流通，更好地服务中国患者的诊疗需求，为提升国民健康水平、推动医疗体系进步贡献力量，助力实现“健康中国2030”战略目标。诺和诺德进博会七年“全勤生”诺和诺德带来了今年刚在中国获批后首展的4款多疾病领域全球创新药，分别为：糖尿病领域，全球首个胰岛素周制剂诺和期，一周仅需注射一次，有效改善胰岛素治疗依从性，开启胰岛素治疗周制剂时代。全球首个口服GLP-1RA诺和忻，每日口服给药，即可强效降糖，兼顾多重代谢获益，标志着GLP-1RA类药物进入口服时代。肥胖症领域，全球首个用于长期体重管理的GLP-1RA诺和盈，能够实现平均17%（17.6kg）的体重降幅，并为患者带来超越减重的多重健康获益，开启中国肥胖症治疗的新格局。中国首个长效重组凝血因子Ⅷ诺易特（注射用培妥罗凝血素a），开启血友病A长效重组凝血因子替代治疗的新时代。碧迪医疗碧迪医疗将围绕“BD Excellence，为未来健康而卓越”这一主旨，通过“前沿生命科学及体外诊断、智能监护及智慧医疗、外科介入及癌症诊疗、银发健康及居家护理”以及新品首发五大主题展区，全方位展示碧迪医疗创新医疗技术成果及最新产品解决方案。其中，碧迪医疗首次创新性地设立了“银发健康及居家护理”专区，旨在推动健康中国与经济发展协同并进，实现两者的新质同步繁荣。借助“进博号列车”这一全新参展理念，碧迪医疗将携15款全球首发、中国首发、限定首发的创新展品以“超光速”闪现第七届进博会，期待通过进博会强大的溢出效应，以“中国速度”加速医疗科技创新落地转化，其中包含1款全球首秀、11款中国首发、1款限定首发以及2款预热新品，覆盖外周介入、专业外科、肿瘤诊断、泌尿及重症监护等多个领域。卡尔史托斯卡尔史托斯将以“光耀新途熠彩华章”为主题，通过集成卡尔史托斯核心内外镜影像家族产品的实景模拟的OR1一体化手术室、覆盖从首至足12个专科的解决方案专区和首次设立的本土化产品专区等展示区，全面呈现其在外科领域的多元化产品管线，以及深化本土化战略的持续拓展实践。实景模拟OR1一体化手术室：展现卡尔史托斯基于手术室持续开拓日间诊疗中心、门急诊/呼吸内镜中心、培训中心等新模式，以丰富解决方案满足多样化医疗场景的需求。首次设立本土化产品专区：展示自去年进博会上官宣建设中国制造基地以来的首批国产影像产品样机，是公司持续深化在华发展的重要体现。专科解决方案专区：以覆盖从首至足12个产品线完整解决方案为矩阵，联合展现各科室微创手术全流程。强生医疗作为进博会“七届全勤生”，强生携旗下医疗科技、创新制药两大业务百余款创新产品重磅亮相，其中近四分之一为首发首秀产品。针对发病率在中国位居榜首的肺癌，强生特别呈现了全球首个获批用于治疗非小细胞肺癌的EGFR/MET双特异性抗体Rybrevant，以及全球首台经支气管诊疗肺癌的数字化手术机器人MONARCH。针对心血管疾病，强生推出中国首秀的心力衰竭治疗领域的重磅创新产品Impella CP with SmartAssist介入式左心室辅助泵和全球首发的拥有智能精准压力指示和多孔灌注技术的多电极空腔导管STSF等四款中国乃至全球首发、首秀展品。此外，强生还带来了专为提供全视程视力而设计的创新人工晶状体TECNIS Odyssey™ 赛无级，以及由中国团队研发的全球首发产品新一代抗菌薇乔腔镜口针等。盈康一生盈康一生是海尔集团旗下大健康生态品牌，深耕生命科学、临床医学、生物科技三大产业。今年是盈康一生连续第五年参加进博会，以“盈无界智未来”为主题，携30余款新产品和新方案亮相，重点展示智慧生物样本库、智慧公卫、智慧医疗、智慧血液生态四大核心场景，其中，50%以上是首发首展。本届进博会期间，盈康一生将重磅展出多款全球首发展品——全球第四代生物样本库“生命方舟”、针对脑卒中疾病研发的血管内靶向温度管理系统、专为细胞毒性药物配置自研的全自动肿瘤配液机器人等。此外，还将展出斯特林制冷系列产品、新一代造影增强设备Discovery D系列高压注射器等十余款首发产品。一审| 黄佳二审| 李芳晨三审| 李静芝精彩推荐 CM10 | 集采 | 国谈 | 医保动态 | 药审 | 人才 | 薪资 | 榜单 | CAR-T | PD-1 | mRNA | 单抗 | 商业化 | 国际化｜猎药人系列专题 | 出海启思会 | 声音·责任 | 创百汇 | E药经理人理事会 | 微解药直播 | 大国新药 | 营销硬观点 | 投资人去哪儿 | 分析师看赛道 | 药事每周谈 | 医药界·E药经理人 | 中国医药手册创新100强榜单 | 恒瑞 | 中国生物制药 | 百济 | 石药 | 信达 | 君实 | 复宏汉霖｜翰森 | 康方生物 | 上海医药 | 和黄医药 | 东阳光药 | 荣昌 | 亚盛医药 | 齐鲁制药 | 康宁杰瑞 | 贝达药业 | 微芯生物 | 复星医药｜再鼎医药｜亚虹医药跨国药企50强榜单 | 辉瑞 | 艾伯维 | 诺华 | 强生 | 罗氏 | BMS | 默克 | 赛诺菲 | AZ | GSK | 武田 | 吉利德科学 | 礼来 | 安进 | 诺和诺德 | 拜耳 | 莫德纳 | BI | 晖致 | 再生元

申请上市突破性疗法

2024-10-08

·BioSpace

Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024

Presentations highlight momentum of Pfizer’s portfolio of infectious disease prevention and treatment options NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held in Los Angeles from October 16-19, 2024. Data in 49 abstracts from company- and collaborator-led studies, will highlight the advances Pfizer is making in helping prevent and treat infectious diseases. “Pfizer is at the forefront of vaccine and therapeutic development in respiratory and infectious diseases,” said Annaliesa Anderson, Ph.D., Senior Vice President and Head, Vaccine Research and Development, Pfizer. “IDWeek 2024 provides a crucial platform to showcase our innovative advancements and engage with the scientific community, as we work to effectively tackle the ongoing challenge posed by infectious diseases.” “As we approach another respiratory virus season, the importance of preventive vaccines and treatments to help keep us healthy is more apparent than ever,” said Luis Jodar, Ph.D., Chief Medical Affairs Officer, Vaccines/Antivirals, Pfizer. “We’re excited to present new, meaningful data that we hope will help further inform healthcare providers.” Pfizer will present research from its robust infectious disease portfolio, covering RSV, COVID-19, pneumococcal disease, Lyme disease, meningococcal disease, and serious bacterial and fungal infections. Details for Pfizer-sponsored, investigator-sponsored and collaborative research oral and poster presentations are below: Title/Abstract Number Presenting Name/Type Date/Time (PDT) Location ORAL & LATE-BREAKING PRESENTATIONS 580 - Pharmacokinetics (PK) and Safety of Nirmatrelvir/Ritonavir (NMV/r) in Non-Hospitalized Symptomatic Pediatric Patients Ages 6 Years and Older with COVID-19 Who Are at Increased Risk of Progression to Severe Disease (EPIC-Peds) Jacqueline Gerhart, PhD Oct 19 2:45 – 2:57 PM US PT 403 A 88 - Efficacy of Nirmatrelvir/Ritonavir in High-Risk Trial Participants With Prior SARS-CoV-2 Infection or Vaccination: A Pooled Analysis John M. McLaughlin, PhD Oct 17 10:42 – 10:54 AM US PT 411 165 - Real-world Abrysvo vaccine effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related severe acute respiratory infection (ARI) hospitalizations and emergency department (ED) visits—Kaiser Permanente of Southern California (KPSC), November 2023-April 2024 Sara Tartof, PhD, MPH, (KPSC)* Oct 17 1:45 – 3:00 PM US PT 403A 571 – Safety and Immunogenicity of Coadministered Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine With and Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age Rahsan Erdem, MD Oct 19 1:45 – 2:03 PM US PT 408 A POSTER PRESENTATIONS COVID-19 P - 1194 - Comparison of COVID-19 Inpatient Burden in Hospitalized Children Age < 5years, by SARS-CoV-2 Variant Kathleen M. Andersen, PhD MSc Oct 18 12:15 – 1:30 PM US PT Hall J & K P - 1906 - Early COVID-19 and Severity of Subsequent Omicron Infection in Ontario, Canada Caroline Kassee, MPH (Sinai Health)* Oct 19 12:15 – 1:30 PM US PT Hall J & K P - 1977 - Six-Month Trajectory of Symptoms of COVID-19 Fatigue by Age and BNT162b2 COVID-19 Vaccination Status: A Prospective Study Among Symptomatic US Adults Testing Positive for SARS-CoV-2 at a National Retail Pharmacy Manuela Di Fusco, PhD Oct 19 12:15 – 1:30 PM US PT Hall J & K P - 2047 - Public Health Impact and Economic Value of an Additional Dose of Pfizer-BioNTech XBB.1.5-adapted COVID-19 Vaccine for Older Adults in the United States Alon Yehoshua, PharmD, MS Oct 19 12:15 – 1:30 PM US PT Hall J & K P - 2048 - COVID-19 XBB.1.5 vaccine uptake based on state vaccine registries compared to national survey data Angela Cook, MS Oct 19 12:15 – 1:30 PM US PT Hall J & K P - 2054 - Effectiveness of a Single COVID-19 mRNA Vaccine Dose in Individuals Previously Infected with SARS-CoV-2: A Systematic Review Hannah R. Volkman, PhD, MPH Oct 19 12:15 – 1:30 PM US PT Hall J & K P - 2060 - Effectiveness of BNT162b2 COVID-19 Vaccination Against Long COVID Among Older Adults: A Nationwide Study Manuela Di Fusco, PhD Oct 19 12:15 – 1:30 PM US PT Hall J & K P - 2062 - COVID-19 XBB.1.5-adapted vaccine uptake in immunocompromised individuals using tokenized state vaccine registries Matthew A. Brouillette, MPH Oct 19 12:15 – 1:30 PM US PT Hall J & K P - 2017 - Patient Reported Outcomes of Nirmatrelvir/Ritonavir Treatment for High-risk, Nonhospitalized Adults with Symptomatic COVID-19 Ashley S. Cha-Silva, PharmD, MS Oct 19 12:15 – 1:30 PM US PT Hall J & K Lyme Disease P - 599 - 6-Valent, OspA-Based VLA15 Lyme Disease Vaccine Candidate Against Lyme Borreliosis in a Healthy Pediatric and Adult Study Population: A Phase 2 Study Update James H. Stark, PhD Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 1287 - Incidence of Symptomatic Lyme Borreliosis in Nine European Countries, 2018−2022 Frederick Angulo, DVM PhD Oct 18 12:15 – 1:30 PM US PT Hall J & K P - 1291 - Racial disparities in Lyme disease among beneficiaries of US Medicaid and Medicare L. Hannah Gould, PhD, MS, MBA Oct 18 12:15 – 1:30 PM US PT Hall J & K P - 1293 - Healthcare Costs Associated with Lyme Disease in a U.S. Insured Population Holly Yu, MSPH Oct 18 12:15 – 1:30 PM US PT Hall J & K Meningococcal Disease P - 1299 - Epidemiology of Invasive Meningococcal Disease in the United States: Review of Recent Data and Identified Risk Factors Jessica Presa, MD Oct 18 12:15 – 1:30 PM US PT Hall J & K P - 1304 - Public Health Impact of changes to Meningococcal vaccination platform in the United States Katharina Schley, Dr. rer pol. Oct 18 12:15 – 1:30 PM US PT Hall J & K Pneumococcal disease P - 8 - Assessment of 13-valent pneumococcal conjugate vaccine effectiveness among people living with HIV in the United States Amanda C. Miles, MPH Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 628 - Real-world impact of pneumococcal conjugate vaccines on vaccine serotypes and cross-reacting non-vaccine serotypes Kevin Apodaca, MPH Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 629 - The health and economic impact of the PCV15 and PCV20 priming series during the first year of life in the US Mark Rozenbaum, PhD, M.B.A Oct 17 12:15 – 1:30 PM US PT Hall J & K Respiratory Syncytial Virus (RSV) P - 673 - Respiratory Syncytial Virus (RSV) Hospitalizations During Off-Season Months Among Infants in US Amy W. Law, PharmD Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 674 - The Economic Burden of Infant RSV Among US Caregivers Amy W. Law, PharmD Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 40 - Impact of case and control selection on influenza vaccine effectiveness (VE) among adults aged 40 years and older hospitalized with acute respiratory illness (ARI) during 2022-2023 using a test negative design (TND): secondary analysis of the North America Multi-Specimen Study Negar Aliabadi, MD, MS Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 1204 - Hospitalizations Associated with Respiratory Syncytial Virus (RSV) Illness Among Children and Adolescents in Ontario, Canada Sazini Nzula, PhD Oct 18 12:15 – 1:30 PM US PT Hall J & K P - 1205 - Impact of the COVID-19 Pandemic on Hospitalizations Associated with Respiratory Syncytial Virus (RSV) Illness Among Children and Adolescents in Ontario, Canada Sazini Nzula, PhD Oct 18 12:15 – 1:30 PM US PT Hall J & K P - 677 - Estimation of Respiratory Syncytial Virus-Attributable Hospitalizations Among Older Adults in Japan between 2015 and 2018: An Administrative Health Claims Database Analysis Asuka Yoshida, PhD Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 680 - Estimated Respiratory Syncytial Virus (RSV)-Related Hospitalizations and Deaths Among Adults in Norway between 2010–2019 Caihua Liang, MD, PhD Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 682 - The Risk of Cardiorespiratory Events for Up to 180 days Following Respiratory Syncytial Virus (RSV) Infection Hospitalization: A Self-Controlled Case Series Analysis Caihua Liang, MD, PhD Oct 17 12:15 – 1:30 PM US PT Hall J & K P – 683 – Estimation of RSV-Attributable Cardiovascular and Respiratory Hospitalizations in Adults in Germany, Between 2015-2019 Caroline Beese Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 604 - Preliminary real-world Abrysvo vaccine effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related lower respiratory tract disease (LRTD) hospitalizations and emergency department (ED) visits—Kaiser Permanente of Southern California (KPSC) November 2023-April 2024 Negar Aliabadi, MD, MS Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 53 - Trends in Co-administration of Adult Vaccinations in the US Retail Pharmacy Setting Reiko Sato, PhD Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 603 - Potential Public Health Impact of Respiratory Syncytial Virus (RSV) Vaccines for Prevention of RSV Among Older Adults in the United States Reiko Sato, PhD Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 600 - Efficacy Of a Bivalent RSVpreF Vaccine in Older Adults Across a Second RSV Season John Woodside, PhD Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 596 - Immunobridging Demonstrating Effectiveness of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Adults 18-59 Years of Age at High Risk of Severe RSV Disease in a Phase 3 Trial: The C3671023 MONeT Study Results Elliot N. DeHaan, MD Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 681 - Estimated Incidence of Respiratory Syncytial Virus (RSV)-Related Hospitalizations for Acute Respiratory Infections (ARIs), including Community Acquired Pneumonia (CAP), in Adults in Germany Caihua Liang, MD, PhD Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 605 - Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High and Durable Neutralizing Titers Across an Entire RSV Season Among Older Adults Tarek Mikati, MD, MPH Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 595 - Public Health Impact of RSVpreF Vaccination on Older Adult Disease Outcomes Daniel Eiras, MD, MPH Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 21 - Comparison of Three RSV Vaccine Lower Respiratory Tract Disease Primary Endpoint Definitions for Adult Vaccine Sarah E. Williams, MD. MPH Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 2357 - Respiratory Syncytial Virus (RSV) Disease Burden Among Adults in Primary Care Settings in High-Income Countries: A Systematic Review and Modelling Study You Li; multiple Pfizer co-authors Oct 19 12:15 – 1:30 PM US PT Hall J & K Aztreonam-Avibactam P - 105 - Aztreonam-Avibactam Compared with Adjunctive Colistin Combined with Meropenem for the Treatment of Serious Gram-Negative Bacterial Infections: Subgroup Analysis of the Phase 3 REVISIT Study Heidi Leister-Tebbe, BSN Oct 17 12:15-1:30 PM US PT Hall J & K P - 1080 Aztreonam-Avibactam Activity Against Gram-negative Bacteria Isolated From Patients with Pneumonia from Europe, Asia, and Latin America (2021–2023) Helio S. Sader, MD, PhD, FIDSA Oct 18 12:15 – 1:30 PM US PT Hall J & K P - 1256 - Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Aztreonam-Avibactam Dosing Regimens Susan Raber*, PharmD, MPH Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 1508 - In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolates Producing Multiple β-lactamases Collected Globally as a Part of the ATLAS Global Surveillance Program From 2018-2022 Mark Estabrook*, PhD Oct 17 12:15 – 1:30 PM US PT Hall J & K P - 1509 - In Vitro Activity of Aztreonam-Avibactam Against Enterobacterales Isolated From Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2018-2022 Mark Estabrook*, PhD Oct 18 12:15 – 1:30 PM US PT Hall J & K Isavuconazole P - 1168 - Activity of Isavuconazole and Comparator Agents Against Pediatric Fungal Isolates Collected from 2017–2023 in a Global Surveillance Program Marisa Winkler, MD, PhD Oct 17 12:15 – 1:30 PM US PT Hall J & K Ceftazidime-Avibactam P- 1506 - In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Pseudomonas aeruginosa Collected from Patients with Presumed Hospital- and Community-Acquired Respiratory Tract Infections as a Part of the ATLAS Global Surveillance Program 2018-2022 Mark Estabrook, PhD Oct 17 12:15 – 1:30 PM US PT Hall J & K P- 1507 - In Vitro Activity of Ceftazidime-Avibactam Against Enterobacterales Isolates Producing Multiple β-lactamases Collected Globally as a Part of the ATLAS Global Surveillance Program from 2018-2022 Mark Estabrook, PhD Oct 17 12:15 – 1:30 PM US PT Hall J & K * =multiple Pfizer co-authors Prescribing Information for Pfizer Medicines Please see full Prescribing Information for ABRYSVO ® (Respiratory Syncytial Virus Vaccine) or visit and . Please see full Prescribing Information for COMIRNATY ® (COVID-19 Vaccine, mRNA) or visit . Please see full Prescribing Information for CRESEMBA ® (Isavuconazonium Sulfate) or visit Please see full Prescribing Information for PAXLOVID TM (Nirmatrelvir and Ritonavir) or visit . Please see full Prescribing Information for PREVNAR 20 TM (Pneumococcal 20-valent Conjugate Vaccine) or visit . Please see full Prescribing Information for PREVNAR 13 ® (Pneumococcal 13-valent Conjugate Vaccine). Please see full Prescribing Information for ZAFICEFTA ® (Ceftazidime-Avibactam). About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at . In addition, to learn more, please visit us on and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer . DISCLOSURE NOTICE: The information contained in this release is as of October 8, 2024. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer’s infectious disease pipeline, in-line products and product candidates, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risk and uncertainties include, among other things, uncertainties regarding the commercial success of Pfizer’s infectious disease products and product candidates; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim and preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications, biologics license applications and/or emergency use authorization applications may be filed in any jurisdictions for any potential indication for Pfizer’s product candidates; whether and when any such applications that may be pending or filed for any of Pfizer’s product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer’s products or product candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at and . Contacts Media Contact: PfizerMediaRelations@Pfizer.com +1 (212) 733-1226 Investor Contact: IR@Pfizer.com +1 (212) 733-4848

疫苗临床3期临床2期临床结果

100 项与阿维巴坦钠/氨曲南相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
复杂腹腔感染	欧盟	Pfizer Inc.	2024-04-22
复杂腹腔感染	冰岛	Pfizer Inc.	2024-04-22
复杂腹腔感染	列支敦士登	Pfizer Inc.	2024-04-22
复杂腹腔感染	挪威	Pfizer Inc.	2024-04-22
复杂的尿路感染	欧盟	Pfizer Inc.	2024-04-22
复杂的尿路感染	冰岛	Pfizer Inc.	2024-04-22
复杂的尿路感染	列支敦士登	Pfizer Inc.	2024-04-22
复杂的尿路感染	挪威	Pfizer Inc.	2024-04-22
革兰氏阴性菌感染	欧盟	Pfizer Inc.	2024-04-22
革兰氏阴性菌感染	冰岛	Pfizer Inc.	2024-04-22
革兰氏阴性菌感染	列支敦士登	Pfizer Inc.	2024-04-22
革兰氏阴性菌感染	挪威	Pfizer Inc.	2024-04-22
医院获得性肺炎	欧盟	Pfizer Inc.	2024-04-22
医院获得性肺炎	冰岛	Pfizer Inc.	2024-04-22
医院获得性肺炎	列支敦士登	Pfizer Inc.	2024-04-22
医院获得性肺炎	挪威	Pfizer Inc.	2024-04-22
呼吸机相关性肺炎	欧盟	Pfizer Inc.	2024-04-22
呼吸机相关性肺炎	冰岛	Pfizer Inc.	2024-04-22
呼吸机相关性肺炎	列支敦士登	Pfizer Inc.	2024-04-22
呼吸机相关性肺炎	挪威	Pfizer Inc.	2024-04-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
细菌感染	临床3期	美国	Pfizer Inc.	2020-12-25
细菌感染	临床3期	美国	Allergan Ltd. (Ireland)	2020-12-25
细菌感染	临床3期	中国	Pfizer Inc.	2020-12-25
细菌感染	临床3期	中国	Allergan Ltd. (Ireland)	2020-12-25
细菌感染	临床3期	阿根廷	Pfizer Inc.	2020-12-25
细菌感染	临床3期	阿根廷	Allergan Ltd. (Ireland)	2020-12-25
细菌感染	临床3期	希腊	Pfizer Inc.	2020-12-25
细菌感染	临床3期	希腊	Allergan Ltd. (Ireland)	2020-12-25
细菌感染	临床3期	印度	Pfizer Inc.	2020-12-25
细菌感染	临床3期	印度	Allergan Ltd. (Ireland)	2020-12-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03329092 (REVISIT, Pubmed \| Lancet Infect Dis)	临床3期	革兰氏阴性菌感染 Gram-negative bacteria	422	Aztreonam-avibactam	鹹願網醖選襯衊製艱鏇(膚選鹽夢憲廠襯獵獵鬱) = 範鹽餘鹹淵廠醖繭鑰膚獵鏇餘餘鏇願糧遞範願 (襯觸網簾憲願醖鹽壓鬱 ) 更多	积极	2024-10-01
				Meropenem	鹹願網醖選襯衊製艱鏇(膚選鹽夢憲廠襯獵獵鬱) = 壓構顧廠製選願淵壓範獵鏇餘餘鏇願糧遞範願 (襯觸網簾憲願醖鹽壓鬱 ) 更多
NCT03329092 (REVISIT, CTgov)	临床3期	革兰氏阴性菌感染 \| 复杂腹腔感染 \| 呼吸机相关性肺炎 ... 更多	422	MTZ+ATM-AVI	艱鬱構築製鏇壓簾蓋餘(簾製獵遞餘顧淵鑰構壓) = 鬱觸鏇製獵齋鏇顧範選遞簾窪願襯廠獵鹽製簾 (願顧鏇齋醖醖鑰鹽醖鏇, 壓簾窪淵廠鏇獵鬱鹽選 ~ 範襯鏇鏇醖網鏇鑰鏇鏇) 更多	-	2024-05-07
NCT03580044 (CTgov)	临床3期	细菌感染	15	Avibactam (ATM- AVI+Aztreonam (Aztreonam- Avibactam (ATM- AVI))	夢網範糧選鹽餘憲築齋(鏇齋鑰淵衊壓齋鬱鹽襯) = 築餘遞願構選鏇蓋繭構築顧構製鬱製壓餘觸鏇 (網積夢構獵鑰膚製鑰簾, 淵壓憲齋遞膚窪餘憲淵 ~ 艱壓鑰觸蓋範築觸構廠) 更多	-	2024-02-02
				metronidazole (Best Available Therapy (BAT))	夢網範糧選鹽餘憲築齋(鏇齋鑰淵衊壓齋鬱鹽襯) = 餘憲艱衊範淵遞蓋齋範築顧構製鬱製壓餘觸鏇 (網積夢構獵鑰膚製鑰簾, 蓋糧鹹獵艱艱壓顧鏇觸 ~ 積繭積鏇製鹹簾襯衊廠) 更多
NCT04973826 (CTgov)	临床1期	-	12	AVIBACTAM (ATM-AVI+AZTREONAM	膚鏇鑰鏇蓋糧壓鹽壓選(鑰觸壓遞鬱蓋繭鏇鹹餘) = 獵選醖襯願範選膚鬱鬱衊觸淵範齋簾襯遞夢鹽 (網鬱蓋襯憲製糧淵餘壓, 廠選觸窪構夢鹹網淵顧 ~ 範廠鑰顧願衊願繭壓遞) 更多	-	2023-07-28
NCT04486625 (CTgov)	临床1期	肾功能不全	11	ATM (Cohort 1: Normal Renal Function)	網壓顧鏇廠艱醖窪醖蓋(醖製築淵鹽淵鬱窪壓淵) = 餘夢鏇鬱壓遞顧網網築淵鹽襯鏇衊製網淵齋網 (醖壓淵衊襯積願積遞構, 願糧顧蓋衊鬱構醖鬱遞 ~ 衊齋艱艱衊蓋齋膚範顧) 更多	-	2023-07-28
				ATM (Cohort 2: Severe Renal Impairment)	網壓顧鏇廠艱醖窪醖蓋(醖製築淵鹽淵鬱窪壓淵) = 鬱願衊製憲繭簾淵鑰觸淵鹽襯鏇衊製網淵齋網 (醖壓淵衊襯積願積遞構, 廠製鹹獵夢糧鬱鏇鑰顧 ~ 醖壓夢餘糧網壓齋構衊) 更多
NCT02655419 (Pubmed \| BMJ Open)	临床2期	复杂腹腔感染	40	aztreonam-avibactam (Hospitals 3 and 6)	選製積鹹鬱餘繭繭鏇積(選鏇窪構衊醖衊壓鑰鏇) = 繭衊觸蓋觸鹽築壓廠顧膚積鏇餘糧繭鬱衊簾鬱 (繭築壓選鹹範夢選簾膚 )	-	2022-02-03
NCT02655419 (CTgov)	临床2期	复杂腹腔感染	40	AVI+Metronidazole (ATM-AVI+ Metronidazole:Low AVI Dose Cohort)	獵觸襯壓夢夢顧顧獵築(餘遞鹽窪鏇築淵範獵夢) = 廠窪顧鑰膚鬱糧鬱憲鹽蓋鹹製憲範顧顧淵鏇餘 (餘糧醖膚積顧餘網簾齋, 餘壓獵鹹齋齋鬱淵製鹽 ~ 憲鏇鬱製蓋廠襯獵餘蓋) 更多	-	2019-03-04
				AVI+Metronidazole (ATM-AVI + Metronidazole: High AVI Dose Cohort)	鏇範夢觸憲醖觸醖鏇簾(觸蓋鏇選築憲繭鑰憲選) = 獵淵鏇鏇積製遞窪製築願淵窪鏇選窪鬱鏇網醖 (積壓鑰製觸鏇顧簾鹹蓋, 窪願繭獵鏇構鏇衊齋鹹 ~ 蓋遞獵醖選構壓艱淵遞) 更多